Bio News
Phase 3 trial extended median overall survival by 7.2 months vs. control

Bionmedicines’ combination therapy for HER2-positive gastric cancer has been designated for FDA priority review after demonstrating a median overall survival of 26.4 months in a phase 3 trial. The results came from the “HERIZON-GEA-01” study, which showed improved survival compared with the control group (19.2 months) and a progression-free survival of 12.4 months. The company plans to use the FDA’s “Project Orbis” to accelerate global approvals and expand patient access.

Biobook Team
biobookmedia@biobook.co.krCG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%
U.S. FDA Rejects Summit and Akeso’s PD-1/VEGF Lung Cancer Drug
Biogen Signs $411 Million Deal With Trimtech for Neurodegenerative Diseases
AstraZeneca’s new myasthenia gravis drug cligepa approved in the U.S. and EU
Helus meets primary endpoint in phase 3 trial of depression drug candidate, with 7.6-point improvement over placebo